GILEAD SCIENCES, INC. is 79.9x more valuable than ADMA BIOLOGICS, INC. by market capitalization ($151.05 B vs $1.89 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ADMA | GILD |
|---|---|---|
| Market cap | $1.89 B | $151.05 B |
| US-listed rank | #2130 | #99 |
| Revenue (latest FY) | $510.17M | $29.44B |
| Net income (latest FY) | $146.93M | $8.51B |
| Net margin | 28.8% | 28.9% |
| P/E (trailing FY) | 12.9 | 17.7 |
| SEC filings | 988 | 981 |
GILEAD SCIENCES, INC. is 79.9x more valuable than ADMA BIOLOGICS, INC. by market capitalization ($151.05 B vs $1.89 B).
In their latest fiscal years, ADMA BIOLOGICS, INC. reported $510.17M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: ADMA BIOLOGICS, INC. and GILEAD SCIENCES, INC., or browse the full rankings.